TB-500 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-11-02 and is reviewed periodically as new material appears.
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
Lyophilised peptide powders are hygroscopic, and the fragment absorbs atmospheric moisture when a vial is opened at room temperature. Weighing and aliquoting are normally done quickly in a dry environment, and stock solutions are divided into single-use portions before freezing. Repeated freeze-thaw cycles are avoided because they promote aggregation and can shift the measured content of a vial. These practices are general to synthetic peptides rather than unique to this sequence, but they matter more for short chains kept for long periods.
The seven-residue chain carries several polar and charged side chains, so it dissolves readily in water and in aqueous buffers near neutral pH. No cysteine is present, so disulphide formation is not a concern and reducing agents are unnecessary. Dilute ammonium hydroxide or acetonitrile-water mixtures are sometimes used for stock solutions when initial dissolution is slow. Strongly alkaline conditions and prolonged contact with oxidising agents are avoided because they can modify lysine-containing stretches, and haze in solution usually signals incomplete dissolution or aggregated material.
Identity and purity are checked with reversed-phase high-performance liquid chromatography, which separates the target sequence from truncated or deletion analogues, and with mass spectrometry, which confirms the expected molecular mass. Amino acid analysis and peptide mapping give orthogonal confirmation but are used less often outside specialist laboratories. Counter-ion content varies: material purified on trifluoroacetic acid gradients retains trifluoroacetate, and ion exchange can convert the salt form. Residual water and solvent are measured by Karl Fischer titration or thermogravimetric analysis, and any purity figure should be read together with the method used to obtain it.
| Property | Value | Notes |
|---|---|---|
| Analytical method | LC-MS/MS | Preferred confirmatory technique |
| Appearance | White to off-white powder | Lyophilised form |
| Solubility | Freely soluble in water | Also described in saline |
| Storage temperature | Below -20 °C for powder | Short-term refrigeration for solutions |
| Regulatory status | Prohibited in sport | Listed under peptide hormones |
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Patrick Pierre Sabatier, La pomme de terre, c'est aussi un produit diététique, Robert Laffont, 1993, 275 p. (ISBN 2-221-07631-1). Racines, tubercules, plantains et bananes dans la nutrition humaine, FAP, coll. « Nutrition », no 24, Rome, 1991 (ISBN 92-5-202862-5). Joël Robuchon et Patrick Sabatier, Le Meilleur et le Plus Simple de la pomme de terre, Robert Laffont, 1994, 250 p. (ISBN 2-253-08159-0).
Permission to examine, analyze, verify, and reproduce any records and reports that are important to evaluation of a clinical trial. Any party (e.g., domestic and foreign regulatory authorities, sponsors, monitors, and auditors) with direct access should take all reasonable precautions within the constraints of the applicable regulatory requirement(s) to maintain the confidentiality of subjects' identities and sponsor's proprietary information. (ICH E6) Documentation
Target proteins or DNA sequences are immobilized to the wells of a microtiter plate. Many genetic sequences are expressed in a bacteriophage library in the form of fusions with the bacteriophage coat protein, so that they are displayed on the surface of the viral particle. The protein displayed corresponds to the genetic sequence within the phage. This phage-display library is added to the dish and after allowing the phage time to bind, the dish is washed. Phage-displaying proteins that interact with the target molecules remain attached to the dish, while all others are washed away. Attached phage may be eluted and used to create more phage by infection of suitable bacterial hosts. The new phage constitutes an enriched mixture, containing considerably less irrelevant phage (i.e. non-binding) than were present in the initial mixture. Steps 3 to 5 are optionally repeated one or more times, further enriching the phage library in binding proteins. Following further bacterial-based amplification, the DNA within the interacting phage is sequenced to identify the interacting proteins or protein fragments.
Sources: en.wikipedia.org
Compton had recently founded the American Research and Development Corporation (ARD) to spur the formation of new post-war industries. He introduced the founders to ARD's president, Georges Doriot. Doriot predicted the cancer treatment machines would be a commercial failure. Nevertheless, he perceived HVEC's leaders to be technically capable, and Compton persuaded him that ARD should have a startup with clear human benefits. Among more than 400 applications, Doriot selected the firm among ARD's first three investments. He offered the founders $200,000 in initial capitalization, leaving half the equity to them and their staff consultants. Compton arranged for HVEC to exclusively license MIT's Van de Graaff and Trump patents. Both Compton and Doriot served on the new company's board.
=== Pharmacodynamics === Clascoterone is a steroidal antiandrogen, or antagonist of the androgen receptor (AR), the biological target of androgens such as testosterone and dihydrotestosterone (DHT). In a bioassay, the topical potency of the medication was greater than that of progesterone, flutamide, and finasteride and was equivalent to that of cyproterone acetate. Likewise, it is significantly more efficacious as an antiandrogen than other AR antagonists such as enzalutamide and spironolactone in scalp dermal papilla cells and sebocytes in vitro.
=== Announcement === In October 2022, Casey Newton of Platformer reported that executives at Twitter began discussing the possibility of users being forced to pay for Twitter Blue in order to keep their verification status. Musk publicly announced that verification was "being revamped right now" after Newton's article; according to The Verge, Twitter planned to increase the price of Twitter Blue from US$4.99 per month to US$19.99 per month. Users would have had 90 days to subscribe or face losing their verification status, and employees were told to implement paid verification by November 9 or risk getting fired. Upon the news that Twitter Blue would cost US$19.99 per month, author Stephen King expressed displeasure towards Twitter and stated that he would leave. Musk, replying to King's tweet, proposed that the service should cost US$7.99 instead. In a separate tweet, Musk wrote that Twitter Blue subscribers would receive priority in replies, mentions, and search, fewer advertisements, and longer audio and video. Although paid verification was expected to be launched by November 7, the reintroduction of Twitter Blue was delayed until after the 2022 United States elections on November 9, according to a memo obtained by The New York Times. The announcement of paid verification resulted in several accounts facetiously impersonating Musk, such as those of comedians Kathy Griffin and Sarah Silverman, being suspended. In response, Musk announced that impersonators using Twitter Blue "will be permanently suspended".
=== Initial lesion === Unlike most regions of the body, the oral cavity is perpetually populated by pathogenic microorganisms; because there is a constant challenge to the mucosa in the form of these microorganisms and their harmful products, it is difficult to truly characterize the boundary between health and disease activity in the periodontal tissues. The oral cavity contains over 500 different microorganisms. It is very hard to distinguish exactly which periodontal pathogen is causing the breakdown of tissues and bone. As such, the initial lesion is said to merely reflect "enhanced levels of activity" of host response mechanisms "normally operative within the gingival tissues." Healthy gingiva are characterized by small numbers of leukocytes migrating towards the gingival sulcus and residing in the junctional epithelium. Sparse lymphocytes, and plasma cells in particular, may exist just after exiting small blood vessels deep within the underlying connective tissue of the soft tissue between teeth. There is, however, no tissue damage, and the presence of such cells is not considered to be an indication of a pathologic change. When looking at the gums they look knife like and a very light pink or coral pink. On the contrary, the initial lesion shows increased capillary permeability with "very large numbers" of neutrophils migrating from the dilated gingival plexus into the junctional epithelium and underlying connective tissue (yet remaining within the confines of the region of the sulcus) and macrophages and lymphocytes may also appear.
Sources: en.wikipedia.org
The most common approach is liquid chromatography with tandem mass spectrometry after extraction from blood or urine. Immunoassays exist but are generally treated as screening tools because of cross-reactivity.
Dry lyophilised powder is normally kept frozen and protected from moisture and light. Dissolved material is handled cold and used promptly to limit degradation.
It is not licensed as a medicine in major markets and is distributed as a research chemical. Sports organisations prohibit its use, and some countries restrict import and supply.
Divide it into single-use aliquots and hold them frozen at -20 °C or below, protected from light. Repeated thawing of one container is the main avoidable source of variability.